The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shishkova V.N.

National Medical Research Center for Therapy and Preventive Medicine Federal State Budgetary Institution the Ministry of Health of Russia;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry Federal State Budgetary Educational Institution of Higher Education

Imamgayazova K.E.

National Medical Research Center for Therapy and Preventive Medicine

Kapustina L.A.

Outpatient Clinic No. 69 of the Moscow Healthcare Department

Correction of psychoemotional disorders and short-term prognosis in patients with COVID-19

Authors:

Shishkova V.N., Imamgayazova K.E., Kapustina L.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5): 63‑68

DOI: 10.17116/jnevro202212205163

Read: 2024 times

Contact the author
Table of contents

CORRECTION OF PSYCHOEMOTIONAL DISORDERS AND SHORT-TERM PROGNOSIS IN PATIENTS WITH COVID-19
CORRECTION OF PSYCHOEMOTIONAL DISORDERS AND SHORT-TERM PROGNOSIS IN PATIENTS WITH COVID-19

To cite this article:

Shishkova VN, Imamgayazova KE, Kapustina LA. Correction of psychoemotional disorders and short-term prognosis in patients with COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):63‑68. (In Russ.)
https://doi.org/10.17116/jnevro202212205163

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

This review discusses the importance of the main psychosocial risk factors in the development of chronic non-communicable diseases. The current data on the prevalence of anxiety and depressive disorders in patients with cardiovascular diseases (CVD) are presented. The article summarizes information about the relationship between the development of psychoemotional disorders and CVD, discusses the prospects for the management of such patients in the framework of interdisciplinary cooperation. The main pathogenetic mechanisms of the development of complications, including damage to the central nervous system during infection with a new coronavirus infection, are considered. The significance of the choice of pathogenetic therapy for patients with comorbid somatic and mental diseases in the conditions of a pandemic of a new coronavirus infection is assessed. The results of multicenter placebo-controlled studies on the use of fluvoxamine in patients with a new coronavirus infection of varying severity are discussed.

Keywords:

psychoemotional disorders
cardiovascular diseases
new coronavirus infection
depression
anxiety
fluvoxamine

Authors:

Shishkova V.N.

National Medical Research Center for Therapy and Preventive Medicine Federal State Budgetary Institution the Ministry of Health of Russia;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry Federal State Budgetary Educational Institution of Higher Education

Imamgayazova K.E.

National Medical Research Center for Therapy and Preventive Medicine

Kapustina L.A.

Outpatient Clinic No. 69 of the Moscow Healthcare Department

Received:

31.03.2022

Accepted:

18.04.2022

Close metadata

References:

  1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337.  https://doi.org/10.1093/eurheartj/ehab484
  2. Mosolov SN. Long-term psychiatric sequelae of SARS-COV-2 infection. Curr Ther Mental Disorders. 2021;3:2-23. (In Russ.). https://doi.org/10.21265/PSYPH.2021.31.25.001
  3. Shlyakhto EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the covid-19 pandemic. Russ J Cardiol. 2020;25(3):129-148. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3801
  4. Pedersen SS, von Känel R, Tully PJ, et al. Psychosocial perspectives in cardiovascular disease. Eur J Prev Cardiol. 2017;24(3 suppl):108-115.  https://doi.org/10.1177/2047487317703827
  5. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137(20):2166-2278. https://doi.org/10.1161/CIRCULATIONAHA.117.029652
  6. Harter M, Baumeister H, Reuter K, et al. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom. 2007;76(6):354-360.  https://doi.org/10.1159/000107563
  7. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. https://doi.org/10.1016/S0140-6736(19)31047-5
  8. Kivimaki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-229.  https://doi.org/10.1038/nrcardio.2017.189
  9. Dar T, Radfar A, Abohashem S, et al. Psychosocial Stress and Cardiovascular Disease. Curr Treat Options Cardiovasc Med. 2019;21(5):23.  https://doi.org/10.1007/s11936-019-0724-5
  10. Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687-1196. https://doi.org/10.1093/eurheartj/ehy913
  11. Daskalopoulou M, George J, Walters K, et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men. PLoS One. 2016;11:e0153838. https://doi.org/10.1371/journal.pone.0153838
  12. White JR, Chang CC, So-Armah KA, et al. Depression and human immunodeficiency virus infection are risk factors for incident heart failure among veterans: Veterans Aging Cohort Study. Circulation. 2015;132:1630-1638.
  13. Frasure-Smith N, Lesperance F, Habra M, et al. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation. 2009;120(2):134-140.  https://doi.org/10.1161/CIRCULATIONAHA.109.851675
  14. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention and associations with outcomes. J Am Coll Cardiol. 2006;48(8):1527-1537. https://doi.org/10.1016/j.jacc.2006.06.055
  15. Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290-1306. https://doi.org/10.1177/2047487314543075
  16. Shalnova SA, Deev AD, Metelskaya VA, et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Ther Arch. 2014;12:52-59. (In Russ.). https://doi.org/10.17116/terarkh2014861253-60
  17. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27(23):2763-2774. https://doi.org/10.1093/eurheartj/ehl338
  18. Evstifeeva SE, Shalnova SA, Makarova YuK, et al. Is the population level of anxiety and depression associated with mortality? Data from ESSE-RF study. Cardiovasc Ther Prevention. 2021;20(5):30-39. (In Russ.). https://doi.org/10.15829/1728-8800-2021-3009
  19. Moise N, Khodneva Y, Jannat-Khah DP, et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. https://doi.org/10.1136/bmjopen-2017-017385
  20. Batelaan NM, Seldenrijk A, Bot M, et al. Anxiety and new onset of cardiovascular disease:critical review and meta-analysis. Br J Psych. 2016;208(3):223-229.  https://doi.org/10.1192/bjp.bp.114.156554
  21. Shishkova VN, Kotova MB, Kapustina LA, et al. Issues of pathogenesis of cognitive and psychoemotional disorders in patients with cardiovascular diseases. Therapy. 2020;50(8):158-163. (In Russ.).
  22. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Accessed 2021 Dec 21.  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
  23. Kotova OV, Medvedev VE, Akarachkova ES, et al. COVID-19 and stress-related disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5-2):122-128. (In Russ.). https://doi.org/10.17116/jnevro2021121052122
  24. Helms J, Kremer S, Merdji H, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268-2270. https://doi.org/10.1056/NEJMc2008597
  25. Alpert O, Begun L, Garren P, et al. Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines — two case reports. Brain Behav Immun Health. 2020;9;100173. https://doi.org/10.1016/j.bbih.2020.100173
  26. Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1421. https://doi.org/10.1016/S0140-6736(20)30937-5
  27. Zhou Z, Kang H, Li S, et al. Understanding the neurotropic characteristics of SARSCoV-2: From neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2021;267(8):2179-2184. https://doi.org/10.1007/s00415-020-09929-7
  28. Kurushina OV, Barulin AE. Effects of COVID-19 on the central nervous system. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(1):92-97. (In Russ.). https://doi.org/10.17116/jnevro202112101192
  29. Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688. https://doi.org/10.3389/fphar.2021.652688
  30. Hoertel N. Do the serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Network Open. 2021;4(11):e2136510. https://doi.org/10.1001/jamanetworkopen.2021.36510
  31. Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Molecular Psychiatry. 2021;1(8):34-39.  https://doi.org/10.1038/s41380-021-01309-5
  32. Vai B, Mazza MG, Delli Colli C, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet. Psychiatry. 2021;8(9):797-812.  https://doi.org/10.1016/S2215-0366(21)00232-7
  33. Aishwarya R, Abdullah CS, Morshed M, et al. Sigmar1’s Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology. Front Physiol. 2021;12:705575. https://doi.org/10.3389/fphys.2021.705575
  34. Rosen DA, Seki SM, Fernandez-Castaneda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):34-41. 
  35. Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Mol Psychiatry. 2022;7:1-10.  https://doi.org/10.1038/s41380-021-01432-3
  36. Boulware DR, Abassi M. Fluvoxamine for the treatment of COVID-19. Lancet Glob Health. 2022;10(3):e329. https://doi.org/10.1016/S2214-109X(21)00590-8
  37. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292-2300. https://doi.org/10.1001/jama.2020.22760
  38. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum. Infect Dis. 2021;8(2):ofab050. https://doi.org/10.1093/ofid/ofab050
  39. Reis G, Dos Santos Moreira-Silva EA, Medeiros Silva DC, et al. TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):42-51.  https://doi.org/10.1016/S2214-109X(21)00448-4
  40. Calusic M, Marcec R, Luksa L, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharm. 2022;88(5):2065-2073. https://doi.org/10.1111/bcp.15126
  41. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed 2021 Dec 21.  https://files.covid19treatmentguidelines.nih. gov/guidelines/covid19treatmentguidelines.pdf
  42. Front Line COVID-19 Critical Care Alliance. Prevention & Treatment Protocols for COVID-19. I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS). Accessed 2021 Dec 21.  https://covid19criticalcare.com/covid-19-protocols/i-recover-protocol
  43. BJC HealthCare. COVID-19 Adult Treatment Guidance. Updated October 15, 2021. Accessed 2021 Dec 21.  https://covid19.bjc.org/Portals/0/PDF%20Documents/Clinical%20Resources/BJC_COVID-19_Treatment_Guidance_Final_1.pdf
  44. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19): Version 15 of 02/22/2022. M.: Ministry of Health of the Russian Federation; 2022;245. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.